Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02198092 · ClinicalTrials.gov registry record

Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes

A clinical trial, sponsored by University of Pennsylvania.

Completed
Registry status
24
Enrollment target

NCT02198092: Completed study, sponsored by University of Pennsylvania.

NCT02198092 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02198092 has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
24 participants
Enrollment target

Study Summary

This is an observational, case-control study evaluating the quantitative level of Septin9 in plasma pre- and post-colectomy in hereditary colorectal cancer (CRC) syndrome patients (Familial Adenomatous Polyposis (FAP), Lynch syndrome (also known as HNPCC), and Multiple Adenomatous Polyposis (MAP, also known as MYK/MYH) cases) and genetically related FAP-family members as controls and references.

Interventions

  • OTHER Epi proColon Testing

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2014-07
Est. Completion 2019-08

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02198092

The ClinicalTrials.gov registry entry for NCT02198092 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Epi proColon Testing is the first listed.

NCT02198092 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02198092 about?

NCT02198092 is a clinical study titled "Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes". This is an observational, case-control study evaluating the quantitative level of Septin9 in plasma pre- and post-colectomy in hereditary colorectal cancer (CRC) syndrome patients (Familial Adenomatous Polyposis (FAP), Lynch syndrome (also known as HNPCC), and Multiple Adenomatous Polyposis (MAP, al...

What is the current status of trial NCT02198092?

This trial is currently completed. The enrollment target is 24 participants. The study started on 2014-07. Estimated completion is 2019-08.

What interventions are being tested in trial NCT02198092?

The interventions under investigation include: Epi proColon Testing (OTHER).

Who is sponsoring clinical trial NCT02198092?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.